Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
P21 is a cognitive peptide, at the preclinical stage in the published literature. Synthetic peptide derived from CNTF that promotes neurogenesis without the appetite-suppressing effects of the parent compound.
Synthetic peptide derived from CNTF that promotes neurogenesis without the appetite-suppressing effects of the parent compound.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Intranasal or subcutaneous |
| Doses Reported in Published Studies | 100-400 mcg |
Promotes neurogenesis and cognitive enhancement through CNTF-related pathways without systemic effects.
Synthetic peptide derived from CNTF that promotes neurogenesis without the appetite-suppressing effects of the parent compound.
Promotes neurogenesis and cognitive enhancement through CNTF-related pathways without systemic effects.
P21 is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Intranasal or subcutaneous. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.